Morrisville, NC (PRWEB) November 11, 2014
TearScience and Allaboutvision.com will be conducting a webinar on November 19th, 2014 from 1:00 to 1:30 pm EST that will provide enlightening information on the root cause of roughly 90% of dry eye. Millions suffer from dry eye across the world but recent research has shown that the majority of those who have been diagnosed with dry eye most likely suffer from Meibomian Gland Dysfunction (MGD) and it is treatable.
The webinar will explain how essential oils produced by the Meibomian glands in the eyelids can become blocked. When these glands are blocked, the needed oils are not sufficiently produced and the protective watery layer in the eyes evaporates. This is what causes the sensation of scratchy, tired and irritated eyes associated with dry eye. Dr. Arthur Epstein, one of the nation’s foremost experts on dry eye, will conduct the webinar and will provide informative insight about Meibomian Gland Dysfunction (MGD) and modern treatments that are available today. Mr. Tim Willis, CEO of TearScience, the pioneering company who developed LipiFlow Treatment, will also participate.
The webinar will last approximately 20 minutes and there will be 10 minutes for direct questions. All those who attend the webinar and take a short survey afterwards will receive a $100 voucher good towards a LipiFlow treatment. TearScience Inc. is presenting the Webinar in association with allaboutvision.com.
Learn more about the webinar and register at: http://www.allaboutvision.com/dryeye-webinar
For more information about LipiFlow, please visit http://www.lipiflow.com
TearScience is a medical device company that pioneers breakthrough technologies to significantly improve identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD). MGD, the leading cause of dry eye, is chronic and progressive and affects approximately 300 million people worldwide. The TearScience® Solution for MGD is a comprehensive in-office diagnosis and treatment solution that includes the LipiView®, the Korb Meibomian Gland Evaluator™, and the LipiFlow® Thermal Pulsation System. It is FDA-cleared and has been clinically proven to improve outcomes in patients with MGD. For additional information on how TearScience® is improving gland function and alleviating symptoms for patients with MGD worldwide, please visit http://www.TearScience.com.
919-747-4990 Ext. 406
TearScience and LipiFlow are registered trademarks of TearScience Inc.